JonesResearch lowered the firm’s price target on Opus Genetics (IRD) to $8 from $9 and keeps a Buy rating on the shares following the Q4 report. Topline data from the Viatris-partnered Ryzumvi’s Phhase 3 VEGA-3 and LYNX-2 trials in presbyopia and dim light disturbance is expected in the first half and mid-2025, respectively, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics: Strategic Advances in AAV-Based Gene Therapies and Key Catalysts for Growth
- Opus Genetics reports FY24 EPS ($2.15) vs. (46c) last year
- Opus Genetics sees cash runway into 2H26
- Opus Genetics announces expected 2025 growth drivers
- Opus Genetics presents data on phentolamine ophthalmic solution 0.75%